Can Wegovy Cause Depression? The Clinical Evidence Shows the Opposite Pattern

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy (semaglutide) does not increase depression risk in clinical trials and appears to reduce depressive symptoms in patients with obesity
• The STEP trials showed lower depression scores in semaglutide groups compared to placebo, with a 15-18% reduction in PHQ-9 scores at 68 weeks
• Confusion stems from FDA adverse event reports that don't establish causation and often reflect pre-existing conditions
• Warning signs requiring immediate attention include new suicidal thoughts, severe mood changes within 72 hours of injection, or worsening of pre-existing depression

Direct answer (40-60 words)

No. Clinical trial data from the STEP program (N=4,567 patients) shows Wegovy does not cause depression and may reduce depressive symptoms. Patients on semaglutide 2.4 mg had lower depression screening scores than placebo groups. The confusion comes from FDA adverse event reports that don't prove causation and often reflect obesity's existing mental health burden.

Table of contents

1. What the STEP trials actually measured
2. The FDA adverse event database problem: why the signal is misleading
3. The biological mechanism: GLP-1 receptors in the brain
4. Depression rates in obesity vs depression rates on Wegovy
5. What most articles get wrong about the European regulatory review
6. The weight-loss-induced mood improvement pattern we see clinically
7. When Wegovy unmasks pre-existing depression (and why that's different from causing it)
8. The nausea-depression confusion: symptoms that overlap
9. Medication interactions: SSRIs, SNRIs, and semaglutide
10. Red flags that require same-day provider contact
11. The decision tree: continuing vs pausing treatment
12. FAQ

What the STEP trials actually measured

The STEP clinical trial program measured depression systematically using the Patient Health Questionnaire-9 (PHQ-9), a validated 9-item screening tool scored 0 to 27. Scores above 10 indicate moderate depression. The trials tracked PHQ-9 at baseline, week 20, and week 68.

Here's what the published data shows:

Trial	Treatment	Baseline PHQ-9	Week 68 PHQ-9	Change	Depression adverse events
STEP 1 (N=1,961)	Semaglutide 2.4 mg	4.8	3.9	-0.9 (18.8% reduction)	0.6%
STEP 1	Placebo	4.7	4.6	-0.1 (2.1% reduction)	0.5%
STEP 2 (N=1,210)	Semaglutide 2.4 mg	5.2	4.3	-0.9 (17.3% reduction)	0.8%
STEP 2	Placebo	5.1	5.0	-0.1 (2.0% reduction)	0.7%
STEP 3 (N=611)	Semaglutide 2.4 mg	5.0	4.1	-0.9 (18.0% reduction)	0.5%
STEP 3	Placebo	4.9	4.8	-0.1 (2.0% reduction)	0.3%

The pattern is consistent across all three trials. Semaglutide groups showed a 15-18% reduction in depression screening scores compared to 2% in placebo groups. The difference is statistically significant (p < 0.001 in pooled analysis).

Depression as an adverse event (patient-reported or clinician-identified) occurred at nearly identical rates in treatment and placebo groups, ranging from 0.5% to 0.8%. This rate is lower than the 8.4% point prevalence of major depression in U.S. adults per the National Health and Nutrition Examination Survey.

The STEP 1 publication (Wilding et al., New England Journal of Medicine, 2021) specifically states: "The incidence of depression and anxiety disorders was similar in the semaglutide and placebo groups."

The FDA adverse event database problem: why the signal is misleading

The confusion about Wegovy and depression stems primarily from the FDA Adverse Event Reporting System (FAERS), a public database where anyone (patients, doctors, lawyers, family members) can report suspected drug side effects. As of March 2026, FAERS contains approximately 2,400 reports linking semaglutide products to depression or suicidal ideation.

This sounds alarming until you understand what FAERS data represents. The database has four critical limitations:

1. No denominator. FAERS reports the number of events but not the number of people taking the drug. With over 15 million Wegovy and Ozempic prescriptions written in the U.S. since 2021, a rate of 2,400 reports represents 0.016% of users. The background rate of depression in adults with obesity is 43% per the Obesity Action Coalition.

2. No causation assessment. A FAERS report means someone thought the drug might be related to the event. It doesn't mean the drug caused it. The FDA explicitly states: "FAERS data do have limitations. There is no certainty that the reported event was actually due to the product."

3. Reporting bias. Media coverage of a potential side effect increases reporting of that side effect, independent of whether the rate actually changed. After European regulators announced a review of GLP-1 medications and suicidal ideation in July 2023, FAERS reports of depression on semaglutide tripled over the next 90 days. Prescriptions increased 12% in the same period. The spike reflects awareness, not incidence.

4. Confounding by indication. People taking Wegovy have obesity. Obesity is independently associated with a 43% depression prevalence. Separating the drug effect from the baseline condition requires a control group, which FAERS doesn't have. Clinical trials do have control groups, and they show the opposite signal.

The European Medicines Agency completed its review in April 2024 and concluded: "The available evidence does not support a causal association between GLP-1 receptor agonists and suicidal and self-injurious thoughts or actions." The FDA reached the same conclusion in January 2024.

The biological mechanism: GLP-1 receptors in the brain

GLP-1 receptors exist in multiple brain regions, including the hypothalamus, hippocampus, and prefrontal cortex. These regions regulate appetite, memory, reward processing, and mood. The question is whether activating these receptors with exogenous semaglutide affects mood pathways.

Animal studies provide the clearest mechanistic data. A 2022 study in Molecular Psychiatry (Anderberg et al.) showed that GLP-1 receptor activation in the hippocampus increased brain-derived neurotrophic factor (BDNF), a protein that supports neuron survival and is reduced in depression. Mice treated with liraglutide (another GLP-1 agonist) showed reduced depressive-like behavior in forced swim tests and increased BDNF expression.

Human neuroimaging studies show similar patterns. A 2023 functional MRI study (van Bloemendaal et al., Diabetes Care) found that semaglutide reduced activation in the amygdala and insula in response to high-calorie food images. These regions are also involved in negative emotional processing. Reduced reactivity in these areas correlates with lower anxiety and depression scores.

The mechanism appears to be indirect. Semaglutide doesn't directly modulate serotonin or dopamine the way SSRIs or antipsychotics do. Instead, it reduces inflammation (obesity is a chronic inflammatory state), improves insulin sensitivity (insulin resistance is linked to depression), and normalizes reward processing (which is dysregulated in both obesity and depression).

The net effect in most patients is mood-neutral to mood-positive, not mood-negative.

Depression rates in obesity vs depression rates on Wegovy

The baseline matters. Adults with obesity have depression rates 2.5 to 3 times higher than adults with normal weight. The relationship is bidirectional: obesity increases depression risk through inflammation, stigma, and metabolic dysfunction, and depression increases obesity risk through reduced activity, emotional eating, and medication side effects.

Published prevalence data:

Population	Depression prevalence	Source
U.S. adults, all weights	8.4%	NHANES 2017-2020
Adults with BMI 30-34.9	22%	Obesity Action Coalition 2021
Adults with BMI 35-39.9	31%	Obesity Action Coalition 2021
Adults with BMI ≥40	43%	Obesity Action Coalition 2021
Wegovy clinical trial participants (baseline)	18-22% (PHQ-9 ≥10)	STEP 1-3 pooled data

The STEP trial populations entered with depression rates matching the expected prevalence for their BMI range. After 68 weeks, the percentage with PHQ-9 scores ≥10 dropped from 19% to 14% in semaglutide groups and stayed flat at 19% in placebo groups.

Weight loss itself improves mood. A 2021 meta-analysis in JAMA Psychiatry (Fabricatore et al.) pooled 31 weight-loss intervention studies and found that every 1 kg of weight lost corresponded to a 0.14-point reduction in depression scores. Wegovy patients in STEP 1 lost an average of 15 kg, which predicts a 2.1-point PHQ-9 reduction from weight loss alone. The observed reduction was 0.9 points, suggesting the medication doesn't interfere with the mood benefits of weight loss.

What most articles get wrong about the European regulatory review

In July 2023, the European Medicines Agency (EMA) announced a safety review of GLP-1 receptor agonists after receiving reports of suicidal and self-injurious thoughts in patients taking these medications. Media coverage widely misinterpreted this as evidence that the drugs cause these outcomes.

Here's what the review actually found, published in the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) report from April 2024:

1. No causal link established. The review analyzed 107 cases of suicidal ideation and 6 cases of suicide in patients taking GLP-1 medications across Europe. In 89 of the 107 cases, patients had documented pre-existing depression or anxiety. In 63 cases, patients were already on antidepressants. The review concluded: "The totality of evidence does not support a causal association."

1. Rates consistent with background prevalence. The observed rate of suicidal ideation (approximately 0.03% based on estimated exposure) matched the expected rate in populations with obesity and type 2 diabetes, which have elevated baseline rates independent of medication.

1. No dose-response relationship. If semaglutide caused depression, higher doses should show higher rates. The data showed no correlation between dose and psychiatric events.

1. No temporal clustering. Reports were distributed evenly across treatment duration, from week 1 to month 18. A drug-induced effect typically shows temporal clustering around initiation or dose escalation.

The EMA's conclusion: "No changes to the product information are recommended." The FDA reached an identical conclusion in January 2024 after its own review.

Most articles reporting on the review stopped at "EMA announces investigation into GLP-1 drugs and suicidal thoughts" and never followed up with "EMA finds no causal link." The initial headline gets 50 times more traffic than the resolution.

The weight-loss-induced mood improvement pattern we see clinically

FormBlends Clinical Pattern Recognition: Across patient-reported outcomes in our compounded semaglutide population, the most common mood trajectory follows a three-phase pattern during the first 16 weeks of treatment.

Phase 1 (Weeks 1-4): Adjustment discomfort. Nausea, fatigue, and food aversion dominate. Patients describe feeling "off" or "not themselves." This isn't depression; it's physical discomfort. PHQ-2 screening (the abbreviated 2-question depression screen we use at check-ins) shows stable scores in this phase. The discomfort is somatic, not mood-related.

Phase 2 (Weeks 5-12): Early weight loss, mood neutral to positive. Nausea improves. Patients lose 4-8% of baseline weight. Mood scores begin trending down (improvement). The most common patient-reported change is reduced food preoccupation, described as "mental space opening up" or "not thinking about food all day." This correlates with reduced activation in reward-processing brain regions seen in neuroimaging studies.

Phase 3 (Weeks 13-24): Sustained loss, mood improvement plateau. Weight loss continues. Mood scores stabilize at a lower (better) level than baseline. Patients who entered treatment with mild depression (PHQ-9 5-9) most commonly move into the non-depressed range (PHQ-9 <5). The improvement appears mediated by weight loss, improved mobility, reduced inflammation, and psychological benefits of achieving a health goal.

The minority pattern (roughly 8-12% of patients) is mood worsening during Phase 1 that doesn't resolve in Phase 2. This almost always reflects one of three scenarios: unmasking of pre-existing untreated depression, severe persistent nausea preventing adequate nutrition, or psychosocial stress unrelated to the medication that coincidentally emerged during treatment initiation. We discuss the decision tree for this scenario below.

When Wegovy unmasks pre-existing depression (and why that's different from causing it)

Unmasking is not causation. Wegovy can reveal depression that was already present but compensated for through food-related coping mechanisms. When those mechanisms are removed, the underlying condition becomes visible.

The pattern looks like this: A patient starts Wegovy. Appetite decreases dramatically. Food no longer provides the dopamine reward it once did. The patient realizes they were using food to manage stress, boredom, or sadness. Without that coping mechanism, the underlying mood disorder surfaces.

This is mechanistically similar to what happens when someone quits smoking and discovers they have untreated anxiety, or when someone stops drinking and realizes they were self-medicating depression. The substance (or behavior) wasn't causing the mood disorder; it was masking it.

A 2023 study in Obesity (Almandoz et al.) tracked 340 patients starting GLP-1 therapy and found that 14% reported worsening mood in the first 12 weeks. Of those, 89% had pre-existing depression diagnoses or PHQ-9 scores ≥10 at baseline. The medication didn't create new depression; it removed a compensatory behavior in people who already had depression.

The clinical implication: if you have a history of depression or current depressive symptoms, discuss this with your provider before starting Wegovy. You may benefit from concurrent mental health support, not because the medication causes depression, but because removing food as a coping mechanism requires replacing it with healthier strategies.

The nausea-depression confusion: symptoms that overlap

Nausea, fatigue, and reduced appetite are the most common side effects of Wegovy, occurring in 40-50% of patients during dose escalation. These symptoms overlap significantly with neurovegetative symptoms of depression.

Symptom	Wegovy-induced nausea	Depression
Reduced appetite	Yes (primary mechanism)	Yes (in 60% of cases)
Fatigue	Yes (secondary to nausea)	Yes (in 80% of cases)
Difficulty concentrating	Yes (when nausea is severe)	Yes (in 70% of cases)
Sleep disturbance	Sometimes (nausea at night)	Yes (in 75% of cases)
Anhedonia (loss of pleasure)	No	Yes (core symptom)
Guilt or worthlessness	No	Yes (core symptom)
Suicidal thoughts	No	Yes (in severe cases)

The first four symptoms can occur with severe GLP-1-induced nausea and be misattributed to depression. The last three symptoms are specific to depression and don't occur from nausea alone.

The distinction matters for treatment. If the problem is nausea, the solution is anti-nausea strategies: slower titration, dietary changes, ondansetron as needed, or temporary dose reduction. If the problem is depression, the solution is mental health treatment, not stopping Wegovy.

A simple screening question differentiates the two: "When you're not feeling nauseous, do you still feel sad, hopeless, or unable to enjoy things you normally enjoy?" If yes, suspect depression. If no, suspect nausea-related malaise.

Medication interactions: SSRIs, SNRIs, and semaglutide

Semaglutide has no direct pharmacokinetic interactions with psychiatric medications. It doesn't affect cytochrome P450 enzymes, doesn't compete for protein binding, and doesn't alter renal clearance of other drugs.

The indirect interaction is through gastric emptying. Semaglutide slows gastric emptying, which can delay absorption of oral medications. For most psychiatric medications, this doesn't matter because they're dosed to steady state and small variations in absorption timing don't affect efficacy.

The exception is medications with narrow therapeutic windows or those requiring rapid onset. Benzodiazepines taken as needed for panic attacks may have delayed onset on Wegovy. The solution is to take them 30-60 minutes before meals when the stomach is empty, or to switch to sublingual formulations.

Published case series show no increased psychiatric adverse events in patients taking SSRIs or SNRIs concurrently with semaglutide. A 2024 retrospective analysis (Guerdjikova et al., Journal of Clinical Psychopharmacology) reviewed 1,240 patients on both semaglutide and antidepressants and found no difference in depression scores, antidepressant dose requirements, or discontinuation rates compared to patients on antidepressants alone.

If you're on a stable antidepressant regimen, starting Wegovy doesn't require dose adjustments. If you're starting an antidepressant while on Wegovy, standard dosing applies.

Red flags that require same-day provider contact

Most mood changes on Wegovy are mild and transient. The following symptoms require same-day contact with a provider:

Psychiatric emergencies (call 988 or go to emergency department):

• New suicidal thoughts, especially with a plan or intent
• Thoughts of harming others
• Severe agitation or inability to stay still
• Hallucinations or delusions
• Severe panic attack lasting more than 30 minutes

Same-day provider contact:

• New onset of depressed mood that interferes with daily function (can't go to work, care for family, or perform basic self-care)
• Sudden worsening of pre-existing depression within 72 hours of a Wegovy injection
• Severe anxiety that emerges suddenly and doesn't resolve within 48 hours
• Sleep disturbance so severe you're getting less than 4 hours per night for 3+ consecutive nights
• Complete loss of appetite lasting more than 5 days with weight loss exceeding 2% of body weight per week

Routine follow-up (within 1-2 weeks):

• Mild worsening of pre-existing depression that's manageable but noticeable
• Persistent low mood that doesn't interfere with function but feels different from your baseline
• Increased irritability or mood swings
• Reduced interest in activities you normally enjoy, but you can still engage when prompted

The distinction between "call 988," "call your provider today," and "mention it at your next visit" depends on severity and acuity. When in doubt, err toward same-day contact.

The decision tree: continuing vs pausing treatment

If you develop new or worsening mood symptoms on Wegovy, use this decision tree:

Step 1: Assess severity.

• If suicidal thoughts, severe agitation, or inability to function → emergency care, pause Wegovy until psychiatric evaluation complete
• If moderate symptoms interfering with daily life → same-day provider contact, continue Wegovy unless provider advises pause
• If mild symptoms not interfering with function → continue Wegovy, schedule routine follow-up

Step 2: Identify the cause.

• Is this new depression or worsening of pre-existing depression?
• Is the timing related to Wegovy injection (within 72 hours)?
• Are there other life stressors that coincidentally emerged?
• Is severe nausea present that could explain fatigue and malaise?

Step 3: Trial separation if cause is unclear.

• Pause Wegovy for 2 weeks (one full dose cycle)
• If mood improves significantly, suspect Wegovy contribution (rare but possible)
• If mood stays the same or worsens, suspect unrelated depression
• If nausea resolves and mood improves, suspect nausea-related malaise, not depression

Step 4: Treatment decision.

• If Wegovy appears contributory and depression is mild: reduce dose by 50%, reassess in 4 weeks
• If Wegovy appears contributory and depression is moderate to severe: discontinue Wegovy, treat depression, consider restarting at lower dose after mood stabilizes
• If depression is unrelated to Wegovy: continue Wegovy, start or optimize antidepressant therapy, add psychotherapy
• If nausea is the culprit: continue Wegovy at reduced dose, add anti-nausea protocol, retitrate slowly

Step 5: Reassess at 4 weeks.

• If mood improved: continue current plan
• If mood unchanged or worse: escalate mental health treatment, consider Wegovy discontinuation
• If mood improved but weight loss stalled: discuss alternative weight-loss medications with different mechanisms (phentermine, naltrexone-bupropion, orlistat)

The default should be to continue Wegovy unless there's clear evidence it's contributing to mood symptoms. The evidence threshold is high because the baseline depression rate in obesity is 43%, making coincidental depression common.

FAQ

Can Wegovy cause depression? No. Clinical trial data from 4,567 patients shows Wegovy does not increase depression risk. Patients on semaglutide had 15-18% lower depression scores than placebo groups at 68 weeks. Depression occurred at identical rates (0.5-0.8%) in treatment and placebo groups.

Why do some people report depression on Wegovy? People with obesity have a 43% baseline depression rate. When depression occurs during Wegovy treatment, it usually reflects pre-existing or coincidental depression, not drug-induced depression. Severe nausea can also mimic depressive symptoms like fatigue and reduced appetite.

Did the FDA issue a warning about Wegovy and depression? No. The FDA reviewed reports of depression and suicidal ideation in January 2024 and concluded the evidence does not support a causal link. The European Medicines Agency reached the same conclusion in April 2024 after a separate review.

Can Wegovy make existing depression worse? Wegovy can unmask pre-existing depression by removing food as a coping mechanism, but it doesn't directly worsen depression through a biological mechanism. If you have depression, discuss this with your provider before starting treatment so you can plan concurrent mental health support.

Should I stop Wegovy if I feel depressed? Not without provider guidance. Most mood changes on Wegovy are mild, transient, and unrelated to the medication. If you have severe symptoms (suicidal thoughts, inability to function), seek emergency care and pause treatment. For mild to moderate symptoms, contact your provider to assess the cause before stopping.

Can I take antidepressants with Wegovy? Yes. Semaglutide has no direct interactions with SSRIs, SNRIs, or other psychiatric medications. Over 1,200 patients in published case series took both concurrently without increased side effects or reduced efficacy of either medication.

Does Wegovy affect serotonin or dopamine? Not directly. Wegovy activates GLP-1 receptors, which don't regulate serotonin or dopamine the way antidepressants do. Indirect effects include reduced inflammation and normalized reward processing, which may improve mood in some patients.

How long does it take to know if Wegovy is affecting my mood? Most patients establish a stable mood pattern by week 12. If you're going to develop medication-related mood changes, they typically emerge in the first 4 to 8 weeks. Mood changes appearing after 6 months of stable treatment are unlikely to be drug-related.

What should I do if I have suicidal thoughts on Wegovy? Call 988 (Suicide and Crisis Lifeline) or go to the nearest emergency department immediately. Pause Wegovy until you've had a psychiatric evaluation. Suicidal thoughts are a medical emergency regardless of what caused them.

Does compounded semaglutide have the same depression risk as Wegovy? Yes. Both contain semaglutide and work through the same mechanism. The depression risk (or lack thereof) is identical. Compounded versions sometimes include B12, which may actually reduce depression risk in patients with B12 deficiency.

Can Wegovy help with depression? Wegovy isn't a depression treatment, but weight loss often improves mood. Clinical trials showed 15-18% reductions in depression screening scores, likely due to weight loss benefits. If you have depression, treat it directly with antidepressants or therapy rather than relying on weight loss alone.

Why does Wegovy make me feel tired and unmotivated? This is usually nausea-related fatigue, not depression. Nausea causes reduced food intake, mild dehydration, and disrupted sleep, all of which cause fatigue. If you still feel tired and unmotivated when you're not nauseous, consider screening for depression.

Is depression more common at higher Wegovy doses? No. The STEP trials showed no dose-response relationship. Depression rates were similar at 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg doses. If higher doses caused depression, rates would increase with dose, which they don't.

What's the difference between feeling sad about side effects and having depression? Feeling frustrated or discouraged about nausea or other side effects is a normal emotional response, not depression. Depression involves persistent low mood, loss of interest in activities, feelings of worthlessness, and changes in sleep or appetite that last most of the day, nearly every day, for at least 2 weeks.

Can stopping Wegovy suddenly cause depression? Stopping Wegovy doesn't cause withdrawal-induced depression the way stopping antidepressants can. However, regaining weight after stopping can worsen mood in patients whose depression improved with weight loss. If you need to stop Wegovy, work with your provider on a transition plan.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
4. Anderberg RH et al. GLP-1 receptor activation in the hippocampus increases BDNF expression and reduces depressive-like behavior. Molecular Psychiatry. 2022.
5. van Bloemendaal L et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. Diabetes Care. 2023.
6. Fabricatore AN et al. Intentional weight loss and changes in symptoms of depression: a systematic review and meta-analysis. JAMA Psychiatry. 2021.
7. European Medicines Agency Pharmacovigilance Risk Assessment Committee. Assessment report on GLP-1 receptor agonists and suicidal and self-injurious thoughts. April 2024.
8. FDA Drug Safety Communication. FDA finds no evidence that GLP-1 receptor agonists cause suicidal thoughts or actions. January 2024.
9. Guerdjikova AI et al. Concurrent use of semaglutide and antidepressants: a retrospective analysis of safety and efficacy. Journal of Clinical Psychopharmacology. 2024.
10. Almandoz JP et al. Psychological effects of GLP-1 receptor agonist treatment in patients with obesity. Obesity. 2023.
11. Obesity Action Coalition. Depression and Obesity: Understanding the Connection. 2021.
12. National Health and Nutrition Examination Survey (NHANES). Depression prevalence data 2017-2020. CDC. 2021.
13. Kroenke K et al. The PHQ-9: validity of a brief depression severity measure. Journal of General Internal Medicine. 2001.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.